Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > On GLP-1 agonists US Senate passes anti-patent thicket bill

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 12, 2024 12:33pm

162 Views

Post# 36130373

RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

By example - July 12, 2024 - "Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies.

The New York-based Big Pharma is hoping to recover from earlier data that showed a twice-daily formulation of oral danuglipron led to modest weight loss with a high level of adverse events and patient discontinuations.

Now, the company is looking to advance the med as a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.”

The irony is that in December 2023, Raymond James steted: “The annals of biotech are of course littered with examples of drugs that failed as [twice a day] formulations (see here), and pivoted to a [once a day] formulation with great success in hyper competitive market segments (/end sarcasm).”

https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering